Altman Advisors Inc. Acquires Shares of 8,850 Zoetis Inc. (NYSE:ZTS)

Altman Advisors Inc. bought a new position in Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 8,850 shares of the company’s stock, valued at approximately $1,729,000.

A number of other large investors have also recently modified their holdings of the stock. Intech Investment Management LLC raised its position in shares of Zoetis by 94.6% in the 1st quarter. Intech Investment Management LLC now owns 2,320 shares of the company’s stock worth $393,000 after acquiring an additional 1,128 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Zoetis by 49.6% in the first quarter. Acadian Asset Management LLC now owns 25,051 shares of the company’s stock worth $4,235,000 after purchasing an additional 8,302 shares in the last quarter. MQS Management LLC bought a new stake in shares of Zoetis during the 1st quarter valued at $443,000. Crewe Advisors LLC bought a new position in shares of Zoetis in the 1st quarter worth about $154,000. Finally, CreativeOne Wealth LLC lifted its position in Zoetis by 16.7% during the 1st quarter. CreativeOne Wealth LLC now owns 13,323 shares of the company’s stock valued at $2,254,000 after acquiring an additional 1,904 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.7 %

ZTS stock opened at $176.87 on Wednesday. The company has a market capitalization of $79.80 billion, a price-to-earnings ratio of 33.00, a PEG ratio of 2.71 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The business has a 50 day simple moving average of $186.47 and a two-hundred day simple moving average of $180.51.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.36 earnings per share. Research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ZTS. Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, BTIG Research lifted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.